HDS CDTR Health IT Core

HDS CDTR 健康 IT 核心

基本信息

项目摘要

Diabetes mellitus is a significant health burden in the United States, affecting more than 20,000,000 people and costing more than $100 billion annually. The prevalence of Type 2 diabetes (T2DM) is growing rapidly; the CDC estimates that up to 1/3 of Americans will have diabetes by the year 2050. The burden of T2DM is particularly great among ethnic minority populations and those of lower socioeconomic status. The evidence base for the prevention and care of T2DM is one of the most well-established of any chronic illness: clinical trials have shown the efficacy of cardiometabolic therapies in preventing mortality and morbidity in diabetes, and programs such as the Diabetes Prevention Program (DPP) have demonstrated that diabetes can be prevented in high-risk patients. However, the overall quality of care for diabetes remains sub-optimal, significant disparities in diabetes care and prevention persist, and there are very few effective populationbased efforts to systematically reduce prevent diabetes and reduce diabetes risk. Programs that can effectively translate high-quality, evidence-based diabetes prevention and treatment into widespread practice are desperately needed. In response to this need, diabetes researchers at the Kaiser Permanente Northern California Division of Research, HealthPartners Institute for Education and Research, Harvard Pilgrim Health Care Institute, and the University of California San Francisco (UCSF) created the Health Delivery Systems Center for Diabetes Translational Research (HDS-CDTR) in 2011 (P30 DK092924). This CDTR fosters and supports translational research in diabetes within health care delivery systems affiliated with the Health Care Systems Research Network (formerly known as the HMO Research Network) and with UCSF. The HDS- CDTR brings together a multi-disciplinary network of well-established investigators with a strong history of receiving federal and foundation funding in diabetes translational research. The HDS-CDTR is structured around three Translational Research Cores in the areas of health care disparities; diabetes and obesity prevention; and health information technology. HDS-CDTR investigators have strong relationships with delivery systems, ranging from large integrated delivery systems to networks of safety net providers that serve as key partners for translating effective interventions into real-world clinical settings. Our CDTR will continue to be a strong resource to underresourced delivery systems across the U.S. through its Resource Core, which will continue and expand our support of these systems in their efforts to provide high quality diabetes prevention and care. In addition, the HDS-CDTR is expanding its mission to address disparities through the creation of a new Core for Underserved Populations that will develop a strong partnership with junior and senior Underrepresented Minority (URM) investigators at the Morehouse School of Medicine.
糖尿病在美国是一个重大的健康负担,影响着超过 20,000,000 人 人,每年花费超过 1000 亿美元。 2 型糖尿病 (T2DM) 的患病率正在上升 迅速; CDC 估计,到 2050 年,多达 1/3 的美国人将患有糖尿病。 T2DM 在少数民族人群和社会经济地位较低的人群中尤其严重。这 T2DM 预防和护理的证据基础是所有慢性疾病中最完善的证据基础之一: 临床试验表明,心脏代谢疗法在预防死亡率和发病率方面具有功效 糖尿病,糖尿病预防计划 (DPP) 等计划已证明糖尿病可以 在高危患者中应予以预防。然而,糖尿病护理的整体质量仍然不理想, 糖尿病护理和预防方面仍然存在显着差异,并且基于人群的有效方法很少 努力系统地预防糖尿病并降低糖尿病风险。可以有效地 将高质量、循证的糖尿病预防和治疗转化为广泛的实践 迫切需要。 为了满足这一需求,凯撒医疗机构北加州分部的糖尿病研究人员 研究机构:HealthPartners 教育与研究学院、哈佛 Pilgrim 医疗保健研究所以及 加州大学旧金山分校 (UCSF) 创建了糖尿病健康服务系统中心 2011 年转化研究 (HDS-CDTR) (P30 DK092924)。该 CDTR 促进并支持转化 附属于医疗保健系统研究的医疗保健提供系统内的糖尿病研究 网络(以前称为 HMO 研究网络)并与 UCSF 合作。 HDS-CDTR 汇集了 由完善的调查员组成的多学科网络,具有接收联邦和 糖尿病转化研究的基金会资助。 HDS-CDTR 围绕三个转化结构构建 医疗保健差异领域的研究核心;糖尿病和肥胖症的预防;和健康信息 技术。 HDS-CDTR 调查人员与交付系统有着密切的关系,范围从大型 安全网提供商网络的综合交付系统,作为翻译的主要合作伙伴 对现实世界临床环境的有效干预。我们的 CDTR 将继续成为资源不足的强大资源 通过其资源核心在美国各地建立交付系统,这将继续并扩大我们的 支持这些系统努力提供高质量的糖尿病预防和护理。此外, HDS-CDTR 正在扩大其使命,通过为服务不足者创建新的核心来解决不平等问题 将与初级和高级少数族裔 (URM) 建立牢固伙伴关系的人群 莫尔豪斯医学院的研究人员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICK J O'CONNOR其他文献

PATRICK J O'CONNOR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICK J O'CONNOR', 18)}}的其他基金

Reducing Clinical Inertia in Obesity Management of Diabetes in Primary Care: Cluster-Randomized Trial
减少初级保健中糖尿病肥胖管理的临床惯性:整群随机试验
  • 批准号:
    10682132
  • 财政年份:
    2021
  • 资助金额:
    $ 5.35万
  • 项目类别:
Reducing Clinical Inertia in Obesity Management of Diabetes in Primary Care: Cluster-Randomized Trial
减少初级保健中糖尿病肥胖管理的临床惰性:整群随机试验
  • 批准号:
    10394959
  • 财政年份:
    2021
  • 资助金额:
    $ 5.35万
  • 项目类别:
Reducing Clinical Inertia in Obesity Management of Diabetes in Primary Care: Cluster-Randomized Trial
减少初级保健中糖尿病肥胖管理的临床惯性:整群随机试验
  • 批准号:
    10182788
  • 财政年份:
    2021
  • 资助金额:
    $ 5.35万
  • 项目类别:
Reducing Clinical Inertia in Obesity Management of Diabetes in Primary Care: Cluster-Randomized Trial
减少初级保健中糖尿病肥胖管理的临床惯性:整群随机试验
  • 批准号:
    10676402
  • 财政年份:
    2021
  • 资助金额:
    $ 5.35万
  • 项目类别:
Reducing Clinical Inertia in Obesity Management of Diabetes in Primary Care: Cluster-Randomized Trial
减少初级保健中糖尿病肥胖管理的临床惰性:整群随机试验
  • 批准号:
    10618142
  • 财政年份:
    2021
  • 资助金额:
    $ 5.35万
  • 项目类别:
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
成人糖尿病患者降糖疗法的心血管益处和安全性
  • 批准号:
    9292370
  • 财政年份:
    2014
  • 资助金额:
    $ 5.35万
  • 项目类别:
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
成人糖尿病患者降糖疗法的心血管益处和安全性
  • 批准号:
    8896048
  • 财政年份:
    2014
  • 资助金额:
    $ 5.35万
  • 项目类别:
HDS CDTR Health IT Core
HDS CDTR 健康 IT 核心
  • 批准号:
    10016268
  • 财政年份:
    2011
  • 资助金额:
    $ 5.35万
  • 项目类别:
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
优先临床决策支持以降低心血管风险
  • 批准号:
    8442364
  • 财政年份:
    2010
  • 资助金额:
    $ 5.35万
  • 项目类别:
Prioritized Clinical Decision Support to Reduce Cardiovascular Risk
优先临床决策支持以降低心血管风险
  • 批准号:
    8249864
  • 财政年份:
    2010
  • 资助金额:
    $ 5.35万
  • 项目类别:

相似国自然基金

干旱内陆河高含沙河床对季节性河流入渗的影响机制
  • 批准号:
    52379031
  • 批准年份:
    2023
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目
沿纬度梯度冠层结构多样性变化对森林生产力的影响
  • 批准号:
    32371610
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
开放与二元结构下的中国工业化:对增长与分配的影响机制研究
  • 批准号:
    72373005
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
基于MF和HPLC-ICP-MS监测蛋白冠形成与转化研究稀土掺杂上转换纳米颗粒对凝血平衡的影响机制
  • 批准号:
    82360655
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
高寒草灌植被冠层与根系结构对三维土壤水分动态的影响研究
  • 批准号:
    42301019
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
  • 批准号:
    10751106
  • 财政年份:
    2024
  • 资助金额:
    $ 5.35万
  • 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
  • 批准号:
    10462257
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
  • 批准号:
    10678062
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
  • 批准号:
    10678341
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
A role for cardiomyocyte pannexin 1 in non-ischemic heart failure
心肌细胞pannexin 1在非缺血性心力衰竭中的作用
  • 批准号:
    10680109
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了